Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Xiong, Xi"'
Publikováno v:
Annu Rev Pharmacol Toxicol
The abuse of illicit psychostimulants such as cocaine and methamphetamine continues to pose significant health and societal challenges. Despite considerable efforts to develop medications to treat psychostimulant use disorders, none have proven effec
Publikováno v:
Neuropsychopharmacology
Cocaine abuse continues to be a serious health problem worldwide. Despite intense research, there is still no FDA-approved medication to treat cocaine use disorder (CUD). In this report, we explored the potential utility of beta-caryophyllene (BCP),
Autor:
Chloe J. Jordan, Zhi-Bing You, Jianjing Cao, Amy Hauck Newman, Yi He, Zheng-Xiong Xi, Guo-Hua Bi
Publikováno v:
British Journal of Pharmacology. 177:4796-4807
Background and purpose Despite widespread abuse of cocaine, there are no approved treatments for cocaine use disorder. Chronic cocaine use is associated with up-regulated dopamine D3 receptor expression in the brain. Therefore, most D3 -based medicat
Autor:
Catherine A. Schweppe, Jean Lud Cadet, Eliot L. Gardner, Subramaniam Jayanthi, Amy Hauck Newman, Thomas M. Keck, Bruce Ladenheim, Zheng-Xiong Xi, Henriette van Praag, Caitlin Burzynski
Publikováno v:
Psychopharmacology (Berl)
RATIONALE: Abuse of the psychostimulant methamphetamine (METH) can cause long-lasting damage to brain monoaminergic systems and is associated with profound mental health problems for users, including lasting cognitive impairments. Animal models of ME
Publikováno v:
Neuroscience and Biobehavioral Reviews
Highlights • Opioid abuse and overdose have become a national crisis in the USA. • Although several opioid-based pharmacotherapies are available, they are ineffective in long-term relapse prevention. • National Institute on Drug Abuse has liste
Autor:
Roger G. Pertwee, Xiao-Fei Wang, Eliot L. Gardner, Guo-Hua Bi, Pretal P. Muldoon, Zheng-Xiong Xi, Aron H. Lichtman, M. Imad Damaj
Publikováno v:
Br J Pharmacol
BACKGROUND AND PURPOSE: Both types of cannabinoid receptors—CB(1) and CB(2)—regulate brain functions relating to addictive drug‐induced reward and relapse. CB(1) receptor antagonists and CB(2) receptor agonists have anti‐addiction efficacy, i
Autor:
Eric B. Thorndike, Michael H. Baumann, Chloe J. Jordan, Anver Basha Shaik, Charles W. Schindler, Zheng-Xiong Xi, Amy Hauck Newman, Bree A. Humburg
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:602-614
Opioid and cocaine abuse are major public health burdens. Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder. Dopami
Autor:
Stephanie L. Foster, Desta M. Pulley, Christian A. Botz-Zapp, Zheng-Xiong Xi, Briana Hempel, David Weinshenker, Amy Hauck Newman, Daniel F. Manvich, Guo-Hua Bi
Publikováno v:
Behav Brain Res
Recent preclinical studies have reported that pretreatment with the novel and highly-selective dopamine D(3) receptor (D(3)R) antagonists R-VK4–40 or VK4–116 attenuates the abuse-related behavioral effects of oxycodone while enhancing its analges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::903be5a42ee6aa4fc01716c97ddaf769
https://europepmc.org/articles/PMC8403645/
https://europepmc.org/articles/PMC8403645/
Autor:
Ewa Galaj, Zhi Bing You, Vivek Kumar, Rana Rais, Zheng-Xiong Xi, Jianjing Cao, Guo Hua Bi, Amy Hauck Newman, Barbara S. Slusher, Eliot L. Gardner, Alexandra J. Gadiano
Publikováno v:
Neuropsychopharmacology. 44:1415-1424
Prescription opioids such as oxycodone are highly effective analgesics for clinical pain management, but their misuse and abuse have led to the current opioid epidemic in the United States. In order to ameliorate this public health crisis, the develo
Autor:
Guo-Hua Bi, Chloe J. Jordan, Xiang-hu He, Eliot L. Gardner, Yan-Lin Wang, Jia Zhan, Zheng-Xiong Xi
Publikováno v:
Neuropharmacology. 141:11-20
Despite extensive research, the neurobiological risk factors that convey vulnerability to opioid abuse are still unknown. Recent studies suggest that the dopamine D3 receptor (D3R) is involved in opioid self-administration, but it remains unclear whe